Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection

Journal of Virology

Volumn 74, Issue 13, 2000, Pages 5747-5753

  Mori, Kazuyasu ^a   Yasutomi, Yasuhiro ^b   Sawada, Shuzo ^c   Villinger, Francois ^d   Sugama, Kazushige ^e   Rosenwith, Brigitte ^f   Heeney, Jonathan L ^f   Überla, Klaus ^g   Yamazaki, Shudo ^a   Ansari, Aftab A ^d   Rübsamen Waigmann, Helga ^h  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Bayer Yakuhin   (Japan)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Kyurin Corporation   (Japan)

^f BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^g UNIVERSITY OF LEIPZIG   (Germany)

^h BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNE RESPONSE; INFECTION PREVENTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS LOAD;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; COS CELLS; HIV; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MACACA MULATTA; MALE; QUINOXALINES; REVERSE TRANSCRIPTASE INHIBITORS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; VIREMIA;

EID: 0034043248     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.13.5747-5753.2000     Document Type: Article

References (31)

1. Akari, H., K. Mori, K. Terao, I. Otani, M. Fukasawa, R. Mukai, and Y. Yoshikawa. 1996. In vitro immortalization of Old World monkey T lymphocytes with Herpesvirus Saimiri. Virology 218:382-388.
2. Autran, B., G. Carcelain, T. S. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homcostasis and function in advanced HIV disease. Science 277:112-116.
3. Balter, M. 1999. Can immune systems be trained to fight HIV? Science 286:1470-1471.
4. Cocchi, F., A. L. Devico, A. Garzino-Demo, S. K. Arya, R. C. Gallo, and P. Lusso. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270: 1811-1815.
5. Daniel, M. D., K. Kirchhoff, S. C. Czajak, P. K. Shegal, and R. C. Desrosiers. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938-1941.
6. Desrosiers, R. C., J. D. Lifson, J. S. Gibbs, S. C. Czajak, A. Y. Howe, L. O. Arthur, and R. P. Johnson. 1998. Identification of highly attenuated mutants of simian immunodeficiency virus. J. Virol. 72:1431-1437.
7. Finzi, D., J. Blankson, J. D. Siliciano, J. B. Margolick, K. Chadwick, T. Pierson, K. Smith, J. Lisziewick, F. Lori, C. Flexner, T. C. Quinn, R. E. Chaisson, E. Rosenberg, B. Walker, S. Gange, J. Gallant, and R. F. Siliciano. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:512-517.
8. Garzino-Demo, A., R. B. Moss, J. B. Margolick, F. Cleghorn, A. Sill, W. A. Blattner, F. Cocchi, D. J. Carlo, A. L. Devico, and R. C. Gallo. 1999. Spontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free status. Proc. Natl. Acad. Sci. USA 96:11986-11991.
9. Gauduin, M.-C., R. L. Glickman, S. Ahmad, T. Yilma, and R. P. Johnson. 1999. Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production. Proc. Natl. Acad. Sci. USA 96:14031-14036.
10. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
11. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
12. Hiranuma, K., S. Tamaki, Y. Nishimura, S. Kusuki, M. Isogawa, G. Kim, M. Kaito, K. Kuribayashi, Y. Adachi, and Y. Yasutomi. 1999. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol. 80:187-193.
13. Johnson, R. P., R. L. Glickman, J. Q. Yang, A. Kaur, J. T. Dion, M. J. Mulligan, and R. C. Desrosiers. 1997. Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J. Virol. 71:7711-7718.
14. Kestler, H. W., III, D. J. Ringler, K. Mori, D. L. Panicali, P. K. Sehgal, M. D. Daniel, and R. C. Desrosiers. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651-662.
15. Klein, M. R., C. A. van Baalen, A. M. Holwerda, S. R. Kerkhof Garde, R. J. Bende, I. P. M. Keet, J. M. Eeftinck-Schatenkerk, A. D. Osterhaus, H. Schuitemaker, and F. Miedema. 1995. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181:1365-1372.
16. Kleim, J. P., R. Bender, R. Kirsch, C. Meichsner, A. Paessens, M. Rosner, H. Rubsamen-Waigmann, R. Kaiser, M. Wichers, K. E. Schneweis, I. Winkler, and G. Riess. 1995. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents. Chemother. 39:2253-2257.
17. Mori, K., D. J. Ringler, and R. C. Desrosiers. 1993. Restricted replication of simian immunodeficiency virus strain 239 in macrophages is determined by env but is not due to restricted entry. J. Virol. 67:2807-2814.
18. Rosenberg, E. S., J. M. Billingsley, A. M. Caliendo, S. L. Boswell, P. E. Sax, S. A. Kalams, and B. D. Walker. 1997. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278:1447-1450.
19. Rubsamen-Waigmann, H., E. Huguenel, A. Paessens, J. P. Kleim, M. A. Wainberg, and A. Shah. 1997. Second-generation non-nucleosidic reverse transcriptase inhibitor HBY 097 and HIV-1 viral load. Lancet 349:1517.
20. Rubsamen-Waigmann, H., E. Huguenel, A. Shah, A. Paessens, H. J. Ruoff, H. von Briesen, A. Immelmann, U. Dietrich, and M. A. Wainberg. 1999. Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 may differ from pattern selected in vivo. Antivir. Res. 42:15-24.
21. Ruprecht, R., M. Gama-Sosa, and H. D. Rosas. 1988. Combination therapy after retroviral inoculation. Lancet ii:239-240.
22. Tomaras, G. D., S. F. Lacey, C. B. McDanal, G. Ferrari, K. J. Weinhold, and M. L. Greenberg. 2000. CD8+ T cell-mediated suppressive activity inhibits HIV-1 after virus entry with kinetics indicating effects on virus gene expression. Proc. Natl. Acad. Sci. USA 97:3503-3508.
23. Ten Haaft, P., B. Verstrepen, K. Ueberla, B. Rosenwirth, and J. Heeney. 1998. A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J. Virol. 72:10281-10285.
24. Tsai, C. C., K. E. Follis, A. T. Sabo, W. Beck, R. F. Grant, N. Bischofberger, R. E. Benveniste, and R. Black. 1995. Prevention of SIV infection in macaques in (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 270:1197-1199.
25. Uberla, K., C. Stahl-Hennig, D. Bottiger, K. Matz-Rensing, F. J. Kaup, J. Li, W. A. Haseltine, B. Fleckenstein, G. Hunsmann, B. Oeberg, and J. Sodroski. 1995. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc. Natl. Acad. Sci. USA 92:8210-8214.
26. Watson, W., J. Ranchalis, B. Travis, J. McClure, W. Sutton, P. R. Johnson, S. L. Hu, and N. L. Haigwood. 1997. Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival. J. Virol. 71:284-290.
27. Worig, J. K., M. Hezareh, H. F. Günthard, D. V. Havlir, C. C. Ignacio, C. A. Spina, and D. D. Richman. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278:1291-1294.
28. Wyand, M. S., K. H. Manson, M. Garcia-Moll, D. Montefiori, and R. C. Desrosiers. 1996. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 70:3724-3733.
29. + lymphocyte response in acutely infected rhesus monkeys. J. Virol. 67:1707-1711.
30. Zhang, L., B. Ramratnam, K. Tenner-Racz, Y. He, M. Vesanen, S. Lewin, A. Talal, P. Racz, A. S. Perelson, B. T. Korber, M. Markowitz, and D. D. Ho. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340:1605-1613.
31. Zhang, L., S. R. Lewin, M. Markowitz, H. H. Lin, E. Skulsky, R. Karanicolas, Y. He, X. Jin, S. Tuttleton, M. Vesanen, H. Spiegel, R. Kost, J. van Lunzen, H. J. Stellbrink, S. Wolinsky, W. Borkowsky, P. Palumbo, L. G. Kostrikis, and D. D. Ho. 1999. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J. Exp. Med. 190:725-732.